Symbols / LLY $917.50 -0.06%
LLY Chart
About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 821.18B |
| Enterprise Value | 856.80B | Income | 20.64B | Sales | 65.18B |
| Book/sh | 29.66 | Cash/sh | 8.14 | Dividend Yield | 68.00% |
| Payout | 26.14% | Employees | 50000 | IPO | — |
| P/E | 39.98 | Forward P/E | 21.79 | PEG | — |
| P/S | 12.60 | P/B | 30.94 | P/C | — |
| EV/EBITDA | 27.03 | EV/Sales | 13.14 | Quick Ratio | 0.78 |
| Current Ratio | 1.58 | Debt/Eq | 165.31 | LT Debt/Eq | — |
| EPS (ttm) | 22.95 | EPS next Y | 42.12 | EPS Growth | 51.40% |
| Revenue Growth | 42.60% | Earnings | 2026-04-30 | ROA | 19.42% |
| ROE | 101.16% | ROIC | — | Gross Margin | 83.04% |
| Oper. Margin | 44.90% | Profit Margin | 31.67% | Shs Outstand | 892.99M |
| Shs Float | 890.99M | Short Float | 0.85% | Short Ratio | 1.86 |
| Short Interest | — | 52W High | 1133.95 | 52W Low | 623.78 |
| Beta | 0.43 | Avg Volume | 3.03M | Volume | 1.83M |
| Target Price | $1209.34 | Recom | Buy | Prev Close | $918.05 |
| Price | $917.50 | Change | -0.06% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1209.34
Mean price target
2. Current target
$917.50
Latest analyst target
3. DCF / Fair value
$39.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$917.50
Low
$850.00
High
$1500.00
Mean
$1209.34
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | down | HSBC | Hold → Reduce | $850 |
| 2026-02-25 | init | RBC Capital | — → Outperform | $1250 |
| 2026-02-20 | init | Barclays | — → Overweight | $1350 |
| 2026-02-09 | main | Deutsche Bank | Buy → Buy | $1285 |
| 2026-02-05 | main | JP Morgan | Overweight → Overweight | $1300 |
| 2026-02-05 | main | Cantor Fitzgerald | Overweight → Overweight | $1205 |
| 2026-02-05 | main | Wells Fargo | Overweight → Overweight | $1280 |
| 2026-02-05 | main | Morgan Stanley | Overweight → Overweight | $1313 |
| 2026-01-20 | main | Guggenheim | Buy → Buy | $1161 |
| 2025-12-15 | main | B of A Securities | Buy → Buy | $1268 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $1200 |
| 2025-12-04 | main | BMO Capital | Outperform → Outperform | $1200 |
| 2025-12-03 | main | Guggenheim | Buy → Buy | $1163 |
| 2025-11-24 | main | Morgan Stanley | Overweight → Overweight | $1290 |
| 2025-11-24 | main | Bernstein | Outperform → Outperform | $1300 |
| 2025-11-19 | main | Truist Securities | Buy → Buy | $1182 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $1150 |
| 2025-11-13 | main | Morgan Stanley | Overweight → Overweight | $1171 |
| 2025-11-12 | main | Citigroup | Buy → Buy | $1500 |
| 2025-11-10 | down | Freedom Capital Markets | Buy → Hold | $950 |
News
RSS: Latest LLY news- Why Eli Lilly (LLY) Shares Are Plunging Today - Yahoo Finance Wed, 18 Mar 2026 03
- Eli Lilly shares slide after a bearish Wall Street analyst call — here's our view - CNBC ue, 17 Mar 2026 18
- Biggest stock movers Tuesday: DAL, LLY, BYND, LNSR, and more - Seeking Alpha ue, 17 Mar 2026 15
- Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News - TipRanks hu, 19 Mar 2026 14
- Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares - 24/7 Wall St. ue, 17 Mar 2026 16
- Stock Quote & Chart | Eli Lilly and Company - Eli Lilly ue, 17 Mar 2026 20
- LLY Stock Draws Retail Buzz – Here’s Why Its Investigational Drug Retatrutide Became The Talk Of The Town - Stocktwits hu, 19 Mar 2026 04
- Lilly's Phase 3 diabetes drug helped patients lose 36.6 pounds - Stock Titan hu, 19 Mar 2026 10
- Lilly trades flat after data for next-gen obesity drug (LLY) - Seeking Alpha hu, 19 Mar 2026 14
- LLY Shares Boosted by Positive Phase III Diabetes Trial Results - GuruFocus hu, 19 Mar 2026 16
- Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market - CNBC ue, 17 Mar 2026 12
- Eli Lilly and Company $LLY Shares Sold by Groupama Asset Managment - MarketBeat hu, 19 Mar 2026 09
- PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis Wed, 18 Mar 2026 15
- Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts - Bloomberg.com ue, 17 Mar 2026 20
- RBC Capital Markets Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - TipRanks Mon, 16 Mar 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5 | 4958.0 | — | Stock Award(Grant) at price 989.12 per share. | SULZBERGER GABRIELLE | Director | — | 2026-03-16 00:00:00 | D |
| 1 | 16 | 15917.0 | — | Stock Award(Grant) at price 989.12 per share. | LUCIANO JUAN R | Director | — | 2026-03-16 00:00:00 | D |
| 2 | 10 | 9917.0 | — | Stock Award(Grant) at price 989.12 per share. | FYRWALD J. ERIK | Director | — | 2026-03-16 00:00:00 | D |
| 3 | 12 | 12416.0 | — | Stock Award(Grant) at price 989.12 per share. | ALVAREZ RALPH | Director | — | 2026-03-16 00:00:00 | D |
| 4 | 481 | — | — | Stock Gift at price 0.00 per share. | DOZIER ERIC | Officer | — | 2026-02-19 00:00:00 | D |
| 5 | 4 | 4959.0 | — | Stock Award(Grant) at price 1036.05 per share. | SULZBERGER GABRIELLE | Director | — | 2026-02-17 00:00:00 | D |
| 6 | 15 | 15917.0 | — | Stock Award(Grant) at price 1036.05 per share. | LUCIANO JUAN R | Director | — | 2026-02-17 00:00:00 | D |
| 7 | 9 | 9917.0 | — | Stock Award(Grant) at price 1036.05 per share. | FYRWALD J. ERIK | Director | — | 2026-02-17 00:00:00 | D |
| 8 | 11 | 12417.0 | — | Stock Award(Grant) at price 1036.05 per share. | ALVAREZ RALPH | Director | — | 2026-02-17 00:00:00 | D |
| 9 | 184 | nan | — | — | ZAKROWSKI DONALD A | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -671.52M | -682.55M | -777.47M | -129.80M |
| TaxRateForCalcs | 0.20 | 0.16 | 0.20 | 0.08 |
| NormalizedEBITDA | 35.09B | 22.95B | 15.72B | 10.22B |
| TotalUnusualItems | -3.39B | -4.14B | -3.87B | -1.56B |
| TotalUnusualItemsExcludingGoodwill | -3.39B | -4.14B | -3.87B | -1.56B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 20.64B | 10.59B | 5.24B | 6.24B |
| ReconciledDepreciation | 2.00B | 1.77B | 1.53B | 1.52B |
| ReconciledCostOfRevenue | 11.05B | 8.42B | 7.08B | 6.63B |
| EBITDA | 31.69B | 18.81B | 11.85B | 8.66B |
| EBIT | 29.70B | 17.04B | 10.32B | 7.14B |
| NetInterestIncome | -605.40M | -312.30M | -268.80M | -314.40M |
| InterestExpense | 780.60M | 485.90M | 331.60M | 339.80M |
| InterestIncome | 175.20M | 173.60M | 62.80M | 25.40M |
| NormalizedIncome | 23.36B | 14.05B | 8.33B | 7.68B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 20.64B | 10.59B | 5.24B | 6.24B |
| TotalExpenses | 35.48B | 28.00B | 23.80B | 20.26B |
| DilutedAverageShares | 899.30M | 904.06M | 903.28M | 950.18M |
| BasicAverageShares | 894.43M | 897.54M | 899.38M | 950.18M |
| DilutedEPS | 22.95 | 11.71 | 5.80 | 6.57 |
| BasicEPS | 23.08 | 11.80 | 5.83 | 6.57 |
| DilutedNIAvailtoComStockholders | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeCommonStockholders | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncome | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeIncludingNoncontrollingInterests | 20.64B | 10.59B | 5.24B | 6.24B |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | 20.64B | 10.59B | 5.24B | 6.24B |
| TaxProvision | 5.09B | 2.09B | 1.31B | 561.60M |
| PretaxIncome | 25.73B | 12.68B | 6.55B | 6.81B |
| OtherIncomeExpense | -3.96B | -4.36B | -3.77B | -1.21B |
| OtherNonOperatingIncomeExpenses | -571.00M | -219.00M | 97.00M | 358.60M |
| SpecialIncomeCharges | -3.39B | -4.14B | -3.87B | -1.15B |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | 435.00M | 3.80B | 908.50M | 405.20M |
| WriteOff | 484.00M | 861.00M | 68.00M | 244.60M |
| ImpairmentOfCapitalAssets | 236.10M | |||
| RestructuringAndMergernAcquisition | 2.91B | 3.28B | 3.80B | 908.50M |
| GainOnSaleOfSecurity | -49.50M | -20.20M | -410.70M | 176.90M |
| NetNonOperatingInterestIncomeExpense | -605.40M | -312.30M | -268.80M | -314.40M |
| InterestExpenseNonOperating | 780.60M | 485.90M | 331.60M | 339.80M |
| InterestIncomeNonOperating | 175.20M | 173.60M | 62.80M | 25.40M |
| OperatingIncome | 29.70B | 17.04B | 10.32B | 8.28B |
| OperatingExpense | 24.43B | 19.59B | 16.72B | 13.63B |
| ResearchAndDevelopment | 13.34B | 10.99B | 9.31B | 7.19B |
| SellingGeneralAndAdministration | 11.09B | 8.59B | 7.40B | 6.44B |
| GeneralAndAdministrativeExpense | 8.59B | 7.40B | 6.44B | 6.43B |
| OtherGandA | 8.59B | 7.40B | 6.44B | 6.43B |
| SalariesAndWages | -461.70M | -461.90M | -372.90M | -289.70M |
| GrossProfit | 54.13B | 36.62B | 27.04B | 21.91B |
| CostOfRevenue | 11.05B | 8.42B | 7.08B | 6.63B |
| TotalRevenue | 65.18B | 45.04B | 34.12B | 28.54B |
| OperatingRevenue | 65.18B | 45.04B | 34.12B | 28.54B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 50.37M | 50.37M | 50.40M | 450.00K |
| OrdinarySharesNumber | 894.43M | 897.54M | 899.38M | 950.18M |
| ShareIssued | 944.80M | 947.90M | 949.78M | 950.63M |
| NetDebt | 35.23B | 30.38B | 22.41B | 14.17B |
| TotalDebt | 42.50B | 33.64B | 25.23B | 16.24B |
| TangibleBookValue | 14.12B | 2.34B | -1.07B | -629.80M |
| InvestedCapital | 69.04B | 47.92B | 36.00B | 26.89B |
| WorkingCapital | 20.40B | 4.36B | -1.57B | 896.30M |
| NetTangibleAssets | 14.12B | 2.34B | -1.07B | -629.80M |
| CommonStockEquity | 26.54B | 14.27B | 10.77B | 10.65B |
| TotalCapitalization | 67.40B | 42.80B | 29.09B | 25.39B |
| TotalEquityGrossMinorityInterest | 26.54B | 14.27B | 10.86B | 10.78B |
| MinorityInterest | 79.50M | 91.80M | 125.60M | 175.60M |
| StockholdersEquity | 26.54B | 14.27B | 10.77B | 10.65B |
| OtherEquityInterest | -2.99B | -2.98B | -3.01B | -3.01B |
| GainsLossesNotAffectingRetainedEarnings | -2.88B | -4.32B | -4.33B | -3.84B |
| OtherEquityAdjustments | -2.88B | -4.32B | -4.33B | -3.84B |
| TreasuryStock | 49.50M | 44.20M | 50.50M | 52.70M |
| RetainedEarnings | 24.47B | 13.54B | 10.31B | 10.04B |
| AdditionalPaidInCapital | 7.35B | 7.44B | 7.25B | 6.92B |
| CapitalStock | 590.00M | 592.00M | 593.60M | 594.10M |
| CommonStock | 590.00M | 592.00M | 593.60M | 594.10M |
| TotalLiabilitiesNetMinorityInterest | 85.94B | 64.44B | 53.14B | 38.71B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 50.71B | 36.07B | 25.85B | 21.58B |
| OtherNonCurrentLiabilities | 3.97B | 3.48B | 2.24B | 1.82B |
| EmployeeBenefits | 1.30B | 1.44B | 1.31B | 1.95B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.30B | 1.44B | 1.31B | 1.95B |
| TradeandOtherPayablesNonCurrent | 5.88B | 4.06B | 3.85B | 3.71B |
| NonCurrentDeferredLiabilities | 87.30M | 1.73B | ||
| NonCurrentDeferredTaxesLiabilities | 87.30M | 1.73B | ||
| LongTermDebtAndCapitalLeaseObligation | 40.87B | 28.53B | 18.32B | 14.74B |
| LongTermDebt | 40.87B | 28.53B | 18.32B | 14.74B |
| CurrentLiabilities | 35.23B | 28.38B | 27.29B | 17.14B |
| OtherCurrentLiabilities | 8.46B | 6.40B | 3.28B | 2.85B |
| CurrentDebtAndCapitalLeaseObligation | 1.64B | 5.12B | 6.90B | 1.50B |
| CurrentDebt | 1.64B | 5.12B | 6.90B | 1.50B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.38B | 2.09B | 1.65B | 1.06B |
| PayablesAndAccruedExpenses | 22.76B | 14.77B | 15.46B | 11.73B |
| CurrentAccruedExpenses | 17.38B | 11.54B | 11.69B | 8.78B |
| Payables | 5.38B | 3.23B | 3.77B | 2.95B |
| DividendsPayable | 1.35B | 1.17B | 1.02B | 885.50M |
| TotalTaxPayable | 475.10M | 126.90M | ||
| IncomeTaxPayable | 475.10M | 126.90M | ||
| AccountsPayable | 5.38B | 3.23B | 2.60B | 1.93B |
| TotalAssets | 112.48B | 78.72B | 64.01B | 49.49B |
| TotalNonCurrentAssets | 56.85B | 45.98B | 38.28B | 31.46B |
| OtherNonCurrentAssets | 6.99B | 5.72B | 4.99B | 4.34B |
| NonCurrentDeferredAssets | 9.96B | 8.00B | 5.48B | 2.79B |
| NonCurrentDeferredTaxesAssets | 9.96B | 8.00B | 5.48B | 2.79B |
| InvestmentsAndAdvances | 2.80B | 3.22B | 3.05B | 2.90B |
| InvestmentinFinancialAssets | 668.00M | 1.21B | 1.48B | 1.64B |
| HeldToMaturitySecurities | 211.40M | 214.30M | 213.90M | 235.30M |
| AvailableForSaleSecurities | 668.00M | 1.21B | 1.27B | 1.43B |
| LongTermEquityInvestment | 2.13B | 2.01B | 1.57B | 1.26B |
| GoodwillAndOtherIntangibleAssets | 12.42B | 11.94B | 11.85B | 11.28B |
| OtherIntangibleAssets | 6.52B | 6.17B | 6.91B | 7.21B |
| Goodwill | 5.90B | 5.77B | 4.94B | 4.07B |
| NetPPE | 24.67B | 17.10B | 12.91B | 10.14B |
| AccumulatedDepreciation | -12.56B | -11.79B | -11.10B | -10.23B |
| GrossPPE | 37.23B | 28.89B | 24.01B | 20.38B |
| ConstructionInProgress | 13.01B | 8.24B | 5.08B | 2.80B |
| OtherProperties | 13.49B | 11.46B | 10.33B | 9.41B |
| BuildingsAndImprovements | 10.09B | 8.81B | 8.28B | 7.92B |
| LandAndImprovements | 647.00M | 382.00M | 319.80M | 256.60M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 55.63B | 32.74B | 25.73B | 18.03B |
| OtherCurrentAssets | 147.00M | 266.00M | 149.50M | 7.30M |
| PrepaidAssets | 14.31B | 8.34B | 5.54B | 2.95B |
| Inventory | 13.74B | 7.59B | 5.77B | 4.31B |
| InventoriesAdjustmentsAllowances | 62.90M | 102.40M | 8.90M | 34.20M |
| OtherInventories | 43.00M | 63.00M | 102.40M | 8.90M |
| FinishedGoods | 1.93B | 1.22B | 791.70M | 901.20M |
| WorkInProcess | 8.18B | 3.98B | 3.25B | 2.60B |
| RawMaterials | 3.59B | 2.33B | 1.63B | 801.90M |
| Receivables | 20.16B | 13.28B | 11.34B | 8.56B |
| OtherReceivables | 2.40B | 2.27B | 2.25B | 1.66B |
| AccountsReceivable | 17.76B | 11.01B | 9.09B | 6.90B |
| AllowanceForDoubtfulAccountsReceivable | -14.90M | -14.80M | -16.00M | -22.50M |
| GrossAccountsReceivable | 11.02B | 9.11B | 6.91B | 6.70B |
| CashCashEquivalentsAndShortTermInvestments | 7.27B | 3.27B | 2.93B | 2.21B |
| OtherShortTermInvestments | 154.80M | 109.10M | 144.80M | 90.10M |
| CashAndCashEquivalents | 7.27B | 3.27B | 2.82B | 2.07B |
| CashEquivalents | 1.09B | 657.40M | 2.38B | |
| CashFinancial | 1.73B | 1.41B | 1.44B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 5.96B | 414.00M | -3.15B | 4.60B |
| RepurchaseOfCapitalStock | -4.11B | -2.50B | -750.00M | -1.50B |
| RepaymentOfDebt | -778.00M | -664.00M | 0.00 | -1.56B |
| IssuanceOfDebt | 13.17B | 11.42B | 3.96B | 0.00 |
| CapitalExpenditure | -10.85B | -8.40B | -7.39B | -2.99B |
| EndCashPosition | 7.27B | 3.27B | 2.82B | 2.07B |
| BeginningCashPosition | 3.27B | 2.82B | 2.07B | 3.82B |
| EffectOfExchangeRateChanges | 372.00M | -297.00M | 169.00M | -167.60M |
| ChangesInCash | 3.63B | 746.00M | 583.00M | -1.58B |
| FinancingCashFlow | -2.21B | 1.23B | 3.50B | -5.41B |
| CashFlowFromContinuingFinancingActivities | -2.21B | 1.23B | 3.50B | -5.41B |
| NetOtherFinancingCharges | -772.00M | -491.00M | -335.00M | -308.90M |
| CashDividendsPaid | -5.38B | -4.68B | -4.07B | -3.54B |
| CommonStockDividendPaid | -5.38B | -4.68B | -4.07B | -3.54B |
| NetCommonStockIssuance | -4.11B | -2.50B | -750.00M | -1.50B |
| CommonStockPayments | -4.11B | -2.50B | -750.00M | -1.50B |
| NetIssuancePaymentsOfDebt | 8.05B | 8.90B | 8.65B | -62.00M |
| NetShortTermDebtIssuance | -4.34B | -1.85B | 4.69B | 1.50B |
| NetLongTermDebtIssuance | 12.39B | 10.75B | 3.96B | -1.56B |
| LongTermDebtPayments | -778.00M | -664.00M | 0.00 | -1.56B |
| LongTermDebtIssuance | 13.17B | 11.42B | 3.96B | 0.00 |
| InvestingCashFlow | -10.97B | -9.30B | -7.15B | -3.76B |
| CashFlowFromContinuingInvestingActivities | -10.97B | -9.30B | -7.15B | -3.76B |
| NetOtherInvestingChanges | 1.00M | -248.00M | -98.00M | -302.20M |
| NetInvestmentPurchaseAndSale | 319.00M | -303.00M | -223.00M | -244.00M |
| SaleOfInvestment | 964.00M | 374.00M | 508.00M | 463.60M |
| PurchaseOfInvestment | -645.00M | -677.00M | -731.00M | -707.60M |
| NetBusinessPurchaseAndSale | -661.00M | -948.00M | -1.04B | -327.20M |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -661.00M | -948.00M | -1.04B | -327.20M |
| NetIntangiblesPurchaseAndSale | -2.79B | -2.75B | -2.34B | -1.04B |
| SaleOfIntangibles | 218.00M | 601.00M | 1.60B | 95.80M |
| PurchaseOfIntangibles | -3.01B | -3.35B | -3.94B | -1.13B |
| NetPPEPurchaseAndSale | -7.84B | -5.06B | -3.45B | -1.85B |
| PurchaseOfPPE | -7.84B | -5.06B | -3.45B | -1.85B |
| OperatingCashFlow | 16.81B | 8.82B | 4.24B | 7.59B |
| CashFlowFromContinuingOperatingActivities | 16.81B | 8.82B | 4.24B | 7.59B |
| ChangeInWorkingCapital | -8.09B | -5.38B | -3.06B | -800.00K |
| ChangeInOtherCurrentAssets | -3.45B | -793.50M | 1.52B | |
| ChangeInPayablesAndAccruedExpense | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInPayable | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInAccountPayable | 10.19B | 2.61B | 4.27B | 1.69B |
| ChangeInTaxPayable | 346.60M | -359.70M | ||
| ChangeInIncomeTaxPayable | 346.60M | -359.70M | ||
| ChangeInPrepaidAssets | -6.61B | -3.33B | -3.45B | -793.50M |
| ChangeInInventory | -4.67B | -2.51B | -1.43B | -599.70M |
| ChangeInReceivables | -7.00B | -2.15B | -2.45B | -299.60M |
| OtherNonCashItems | 3.53B | 4.11B | 4.12B | 1.37B |
| StockBasedCompensation | 626.00M | 646.00M | 629.00M | 371.10M |
| DeferredTax | -1.71B | -2.68B | -2.34B | -2.19B |
| DeferredIncomeTax | -1.71B | -2.68B | -2.34B | -2.19B |
| DepreciationAmortizationDepletion | 2.00B | 1.77B | 1.53B | 1.52B |
| DepreciationAndAmortization | 2.00B | 1.77B | 1.53B | 1.52B |
| OperatingGainsLosses | -180.00M | -224.00M | -1.88B | 263.50M |
| GainLossOnSaleOfPPE | -180.00M | -224.00M | -1.88B | -156.50M |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | 20.64B | 10.59B | 5.24B | 6.24B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LLY
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|